What Organogenesis Holdings Inc. told the SEC could break it.

Organogenesis depends on a limited group of suppliers and contract manufacturers — including for its Apligraf, Affinity, CYGNUS, Novachor, NuShield, PuraPly Antimicrobial, VIA Matrix and SimpliMax products — some under sole-source or exclusive supply arrangements; the loss of any significant supplier, a disruption to a sole-source supplier's operations, or the unexpected loss of an exclusive supply contract could cause material delivery delays or significant product-development costs and materially adversely affect its business.

“Because we depend upon a limited group of suppliers and manufacturers for our products, including Apligraf, Affinity, CYGNUS, Novachor, NuShield and PuraPly Antimicrobial products, we may incur significant product development costs or experience material delivery delays if we lose any significant supplier”

Many of Organogenesis's regenerative-medicine products require human tissue obtained from human donors, so its business depends on the continued availability of that donor tissue; any disruption in tissue supply — from donor-availability shortfalls, recovery-organization issues, contamination/quality problems, or changes in HCT/P and AATB requirements — could constrain manufacturing and materially adversely affect its results.

“Our products are dependent on the availability of tissue from human donors, and any disruption in supply could adversely affect our business, results of operations, and financial condition.”

Organogenesis is almost entirely dependent on the U.S. market: substantially all of its sales are in the United States and net product revenue generated outside the U.S. represented less than 1% of total net product revenue in all periods presented; while it plans to expand into the EU and Middle East, this concentration leaves its revenue exposed to U.S.-specific reimbursement, regulatory and competitive dynamics with little geographic diversification.

“Currently, substantially all of our sales are in the United States.”

Organogenesis is subject to extensive FDA regulation of its products (as biologics, devices and HCT/Ps — e.g., a $4.7M FDA fee for the ReNu BLA, with potential mandatory labeling revisions, post-market studies or REMS distribution restrictions), and its customers (hospitals, wound-care centers, government facilities, ASCs and physician offices) rely on coverage and reimbursement from Medicare, Medicaid and other third-party payers; adverse regulatory actions or reductions/changes in reimbursement and healthcare-reform price pressure could materially reduce demand and revenue.

“Our customers primarily consist of hospitals, wound care centers, government facilities, ASCs, and physician offices, all of which rely on coverage and reimbursement for our products by Medicare, Medicaid, and other third-party payers.”